Bristol Myers Squibb Embraces Veeva Vault CRM for Enhanced Patient Engagement

Bristol Myers Squibb Embraces Veeva Vault CRM

In a significant development for the pharmaceutical industry, Bristol Myers Squibb (BMS) has announced its commitment to using Veeva Vault CRM, a move poised to reshape how the company interacts with healthcare professionals and ultimately improve patient care. This decision was unveiled during a press conference on September 22, 2025, by Veeva Systems, a leader in cloud solutions tailored for life sciences.

Greg Meyers, Executive Vice President and Chief Digital Officer of BMS, emphasized that this innovative technology is transforming the way they interact with both clients and patients. He stated, "The technology fundamentally reshapes how we interact with our customers and the patients they serve. We are excited to take this next step in our longstanding relationship with Veeva by utilizing Vault CRM. This tool will aid in enhancing how healthcare professionals make informed decisions regarding the increasingly complex array of innovative medications available today."

The integration of advanced artificial intelligence within the CRM system is a cornerstone of this partnership. "By embedding AI at every stage of the customer journey—from delivering valuable insights about our portfolio to how practitioners engage with our field team—Veeva is uniquely positioned to support us in our mission to provide life-changing medicines to patients worldwide," added Meyers.

Peter Gassner, CEO of Veeva, also expressed enthusiasm about this collaboration, saying, "We value the trust and partnership and are committed to supporting Bristol Myers Squibb in its mission to provide transformative medicines for patients with serious diseases. With Vault CRM, we are introducing the next generation of customer relationship management, featuring integrated AI agents designed to improve healthcare professional engagement and expedite the delivery of appropriate treatments to patients."

Vault CRM is part of Veeva’s comprehensive suite of applications and serves as the foundational technology for commercial execution. The initial Veeva AI agents, including pre-call agents, content agents, free-text agents, and voice agents, are expected to roll out by December 2025.

This partnership signifies a major shift in BMS's approach to customer relationship management, leveraging cutting-edge technology to enhance the effectiveness of their communication and service delivery. Veeva has established itself in the life sciences sector with its cloud-based software, data solutions, and business consulting. Currently supporting over 1,500 clients, ranging from some of the world's largest biopharmaceutical firms to emerging biotech companies, Veeva is dedicated to innovation, product excellence, and customer success.

The announcement also includes forward-looking statements regarding Veeva's products and services, emphasizing that while expectations are high, actual outcomes may differ significantly due to various risks and uncertainties.

For those interested in the evolving landscape of pharmaceutical technology, BMS's adoption of Veeva Vault CRM represents a forward-thinking approach aimed at navigating the complexities of modern healthcare management. The integration of AI into customer interactions highlights a pivotal shift in the industry, potentially setting new standards for how pharmaceutical companies engage with healthcare providers and patients alike.

In conclusion, Bristol Myers Squibb's adoption of Veeva Vault CRM marks a significant milestone in its long-term strategy to enhance patient and healthcare professional interactions. As the pharmaceutical industry continues to evolve, partnerships like this will be crucial in leveraging technology to improve healthcare delivery and patient outcomes.